Some Gut Bacteria Both Protect Against and Cause Heart Disease, Study Finds

Coronary artery disease kills more people globally than any other condition, yet the biological levers that tip someone toward or away from it are still being mapped. One increasingly studied lever sits inside the gut: the trillions of microorganisms that ferment food, produce metabolites, and apparently signal directly to the cardiovascular system. A new meta-analysis published in June 2026 by Suchday, Dhabuwala, Desai, and colleagues drills into one bacterial phylum, Firmicutes, and surfaces a finding that is genuinely uncomfortable: the same broad taxonomic group appears to both protect against and cause coronary artery disease, depending on which members of that group are present.

Firmicutes phylum shows contradictory effects on CAD risk

The headline numbers sit in tension with each other. Pooling data from six Mendelian randomization studies, the team found that higher overall abundance of phylum Firmicutes was associated with a statistically significant protective effect on coronary artery disease, with an odds ratio of 0.880 (95% CI: 0.853 to 0.907). At the same time, increased Firmicutes abundance also correlated with elevated CAD risk, with an odds ratio of 1.10 (95% CI: 1.06 to 1.14). Both effects showed low heterogeneity, with I-squared values of 20 percent, and leave-one-out sensitivity analyses confirmed that neither result was driven by a single outlier study. The contradiction is not a statistical artifact. It reflects the biological reality that Firmicutes is a vast phylum containing hundreds of genera with very different metabolic behaviors, and research on gut dysbiosis and CAD risk has long suggested that disruptions in the diversity and abundance of these bacteria are a crucial contributing factor to heart disease rather than a simple cause-and-effect relationship.

Protective versus causative genera in cardiovascular risk

The study's real value is the genus-level breakdown that sits beneath the phylum-level paradox. On the protective side, the analysis identified eight Firmicutes groups associated with lower CAD risk: Clostridiales vadinBB60, Butyricicoccus, Ruminococcus UCG010, Coprococcus 1, Intestinibacter, Ruminiclostridium 6, Anaerotruncus, and family Acidaminococcaceae. Several of these are well-known butyrate producers, and butyrate, a short-chain fatty acid, has established anti-inflammatory properties in gut epithelium. On the causative side, eight other genera were flagged as potentially increasing CAD risk: the Clostridium innocuum group, Turicibacter, Eisenbergiella, Holdemanella, Eubacterium, Coprostanoligenes group, Ruminococcaceae UCG005, and Catenibacterium. The mechanistic picture involves two key metabolite classes: trimethylamine N-oxide (TMAO), which gut bacteria synthesize from dietary choline and carnitine and which has been linked to arterial inflammation, and short-chain fatty acids (SCFAs), which generally support endothelial function and dampen systemic inflammation. Developing therapies that target gut microbiome metabolites like TMAO and SCFAs is now considered a promising frontier in cardiovascular disease prevention, though clinical translation remains early.

How Mendelian randomization strengthens a notoriously difficult causal question

Observational studies of gut bacteria and heart disease are plagued by confounding: diet, medications, age, and illness all reshape microbial communities simultaneously. Mendelian randomization sidesteps much of this problem by using genetic variants as instrumental variables. Because an individual's genetic makeup is determined at conception and is not altered by later lifestyle or disease, genetic variants associated with specific bacterial abundances can stand in as proxies for those abundances, largely free from the usual confounders and from reverse causality, where heart disease itself reshapes the microbiome. Mendelian randomization has been shown to effectively mitigate these biases in previous gut-cardiovascular work. The current meta-analysis pooled results across six such studies, drawing on GWAS data from the MiBio-Gen consortium alongside cardiovascular risk databases including CARDIoGRAMplusC4D, FinnGen, and the UK Biobank. The inverse variance weighted method was the primary analytical tool for estimating associations within the Firmicutes phylum.

What the genus-level map cannot yet tell us

The authors are candid about the limits of what they have built. Identifying a genus as protective or causative in an MR framework is not the same as understanding the mechanism. Most MR studies operate at the family or genus level because that is where reliable genetic instruments currently exist; strain-level and species-level resolution, where the actual metabolic diversity lives, remains largely inaccessible to this method. The study also does not resolve how much of the observed signal travels through TMAO versus SCFAs versus other inflammatory pathways, and the field as a whole still struggles to move from correlation to causation in a way that translates into consistent clinical benefit. Furthermore, patients with coronary heart disease already show significant alterations in gut flora composition, which means disentangling predisposing microbial states from disease-induced changes requires prospective designs that are still scarce.

Microbiome-targeted heart disease therapies on the horizon

Despite those caveats, the genus-level map the team has produced is the kind of granular data that therapeutic development needs. If Butyricicoccus and Coprococcus consistently protect against CAD while Turicibacter and Catenibacterium consistently raise risk, then dietary interventions, prebiotics, or probiotic formulations designed to shift the ratio of these groups become scientifically tractable targets rather than speculative ones. The authors call for deeper mechanistic research at lower taxonomic levels, essentially species and strain resolution, before clinical trials could responsibly be designed around these specific genera. Given that coronary artery disease remains the leading cause of death in most high-income countries, and given that conventional risk factors like LDL cholesterol and blood pressure explain only part of the population burden, the gut microbiome pathway is one the field cannot afford to treat as peripheral. The Firmicutes paradox this meta-analysis documents is not a problem to be embarrassed about; it is a map of where the important questions now live.

Evidence rating

EMERGING — 90/100

Caveats:

• Mendelian randomization infers causality from genetic proxies rather than direct intervention, so residual confounding and pleiotropy cannot be fully excluded.
• The study pools only six source studies, all drawing from overlapping GWAS databases (MiBioGen, UK Biobank, FinnGen), which limits true independence of replication.
• The contradictory finding — that Firmicutes as a phylum is simultaneously protective and causative — reflects the heterogeneity within this broad taxonomic group and underscores that phylum-level conclusions have limited clinical utility.
• Funding was not disclosed, so potential conflicts of interest cannot be assessed.
• Mechanistic pathways (TMAO, SCFAs) are proposed but not directly measured in this analysis; the causal chain remains partially inferred.

Meta-analysis of six Mendelian randomization studies leveraging large GWAS consortia (MiBioGen, CARDIoGRAMplusC4D, FinnGen, UK Biobank). Mendelian randomization strengthens causal inference relative to standard observational designs, but pooling studies that share the same underlying genetic databases limits independence of replication. The contradictory phylum-level findings (both protective and causative effects) reflect genuine within-phylum heterogeneity rather than analytical error, and genus-level mechanisms remain partially inferred rather than experimentally validated.